

Resource Summary Report

Generated by [dkNET](#) on Jul 31, 2026

I?B? (L35A5) Mouse mAb (Amino-terminal Antigen)

RRID:AB_390781

Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 4814, RRID:AB_390781)

Antibody Information

URL: http://antibodyregistry.org/AB_390781

Proper Citation: (Cell Signaling Technology Cat# 4814, RRID:AB_390781)

Target Antigen: IkappaB-alpha

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P, IF-IC, F. Consolidation: AB_10828207, AB_10693636.

Antibody Name: I?B? (L35A5) Mouse mAb (Amino-terminal Antigen)

Description: This monoclonal targets IkappaB-alpha

Target Organism: monkey, rat, pig, mouse, bovine, human

Clone ID: Clone L35A5

Defining Citation: [PMID:28238890](#), [PMID:27565346](#)

Antibody ID: AB_390781

Vendor: Cell Signaling Technology

Catalog Number: 4814

Alternative Catalog Numbers: 4814S, 4814P

Record Creation Time: 20260311T190913+0000

Record Last Update: 20260311T190946+0000

Ratings and Alerts

No rating or validation information has been found for I?B? (L35A5) Mouse mAb (Amino-terminal Antigen).

No alerts have been found for I?B? (L35A5) Mouse mAb (Amino-terminal Antigen).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 136 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zhang S, et al. (2026) BST2 expression at astrocyte borders promotes microglial recruitment via the C3/C3aR signaling. *Neuron*, 114(1), 67.

Bernaleau L, et al. (2025) CCDC134 controls TLR biogenesis through the ER chaperone Gp96. *The Journal of experimental medicine*, 222(3).

Lish AM, et al. (2025) CLU alleviates Alzheimer's disease-relevant processes by modulating astrocyte reactivity and microglia-dependent synaptic density. *Neuron*, 113(12), 1925.

Graß C, et al. (2025) LUBAC modulates CBM complex functions downstream of TRAF6 in T cells. *Nature communications*, 16(1), 9899.

Borar P, et al. (2025) Dual-specific autophosphorylation of kinase IKK2 enables phosphorylation of substrate I?B? through a phosphoenzyme intermediate. *eLife*, 13.

Qin Z, et al. (2025) Co-targeting BMI1 and MYC to eliminate cancer stem cells in squamous cell carcinoma. *Cell reports. Medicine*, 6(5), 102077.

Hirai M, et al. (2025) HHV-6B ribonucleotide reductase sequesters NF-?B subunit p65 to inhibit innate immune responses. *iScience*, 28(2), 111710.

Wang Z, et al. (2025) NANS suppresses NF-?B signaling to promote ferroptosis by perturbing iron homeostasis. *Cell reports*, 44(5), 115701.

Ruan YH, et al. (2025) Intracellular IL1? in Peritumoral Monocytes Induces IL8 Production and Inhibits Mitophagy to Promote Stemness and Metastasis of Hepatocellular Carcinoma. *Cancer research*, 85(21), 4164.

Li S, et al. (2025) Glutamine synthetase modulates YAP activation by stabilizing LATS under glutamine homeostasis. *Cell reports*, 44(12), 116620.

Pang SJ, et al. (2025) RNA polymerase II subunit 5-mediating protein limits TLR4-induced innate immune activation in macrophages by inhibiting IKK?/NF-?B signaling during

sepsis. Cell communication and signaling : CCS, 23(1), 274.

Xie M, et al. (2025) Tumor-resident probiotic *Clostridium butyricum* improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression. Cancer cell.

Li Q, et al. (2025) SUV39H1-dependent methyl-degron is a critical regulator of skeletal homeostasis. Cell reports, 44(7), 115910.

Lish AM, et al. (2025) Astrocyte induction of disease-associated microglia is suppressed by acute exposure to fAD neurons in human iPSC triple cultures. Cell reports, 44(6), 115777.

Lauriola A, et al. (2025) The E3 ligase RNF32 controls the I κ B kinase complex and NF- κ B signaling in intestinal stem cells. Molecular cell, 85(22), 4254.

Anany MA, et al. (2025) Valence and avidity determine the agonistic activity of anti-TNFR2 nanobody fusion proteins. Cell chemical biology.

Sarkar R, et al. (2025) The ZFP36-FTO axis is a key regulator of macrophage activation and a druggable therapeutic target of sepsis. iScience, 28(12), 114060.

Cui Q, et al. (2025) MIF-ACKR3 causes irreversible fat loss by impairing adipogenesis in cancer cachexia. Cell metabolism, 37(4), 954.

Zhang X, et al. (2025) Intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis through the gut-liver axis. Nature metabolism, 7(1), 102.

Du XY, et al. (2025) Attenuating α -synuclein pathology in mice with in situ engineered astrocytes. Translational neurodegeneration, 14(1), 58.